Akebia Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Discuss Recent Business Highlights
Rhea-AI Summary
Akebia Therapeutics (Nasdaq: AKBA) will release fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, before market open. A conference call to discuss results and recent business highlights will be held on Thursday, February 26, 2026 at 8:00 a.m. EST.
Investors must register to receive dial‑in details; a live webcast and an online archive will be available via the Investors section of Akebia's website.
Positive
- None.
Negative
- None.
News Market Reaction – AKBA
On the day this news was published, AKBA declined 0.85%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
AKBA is down 1.67% with peers mixed: AQST (-1.03%) and SIGA (-1.04%) also lower, while ORGO and DVAX show small gains or are flat, indicating a modest downside tilt across select specialty pharma names rather than a purely idiosyncratic move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Feb 04 | Conference appearance | Neutral | -2.8% | Participation in Guggenheim biotech summit with webcast access for investors. |
| Feb 02 | Inducement grants | Neutral | +2.2% | Stock options granted to new hires under Nasdaq Listing Rule 5635(c)(4). |
| Jan 12 | Corporate update | Positive | -7.9% | Vafseo revenue expectations and detailed 2026 pipeline and trial timelines. |
| Jan 06 | Clinical trial start | Positive | -2.6% | First patient dosed in Phase 2 praliciguat study for FSGS. |
| Jan 05 | Inducement grant | Neutral | -2.6% | New employee stock option grant with four-year vesting and 10-year term. |
Recent news has often been met with negative price reactions, even for clinical and corporate updates that appear strategically positive.
Over the past months, Akebia issued several corporate and clinical updates, including inducement grants, conference participation, and key pipeline milestones. On Jan 12, 2026, it highlighted Vafseo commercialization, a broad dialysis access base of ~275,000 patients, and detailed timelines for the VOICE and VOCAL studies, yet shares fell 7.89%. The first patient dosing in a praliciguat Phase 2 FSGS trial on Jan 6, 2026 also saw a negative reaction. Against this backdrop, the newly announced Feb 26, 2026 earnings call fits into a steady cadence of updates.
Market Pulse Summary
This announcement sets the date of Akebia’s fourth quarter and full-year 2025 earnings call on Feb 26, 2026, adding to a steady flow of recent corporate and clinical updates. Prior communications highlighted Vafseo’s access to ~275,000 dialysis patients, Phase IV VOICE enrollment of >2,100 patients, and multiple Phase 2 efforts. Investors may focus on how reported financials track against the indicated Vafseo revenue range and existing trial timelines.
AI-generated analysis. Not financial advice.
Akebia to Host Conference Call on February 26 at 8:00 a.m. EST
CAMBRIDGE, Mass., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the fourth quarter and full year ended December 31, 2025 on Thursday, February 26, 2026, prior to the open of financial markets.
Akebia will host a conference call on Thursday, February 26, 2026, at 8:00 a.m. EST to discuss its financial results and recent business highlights. To access the call, please register by clicking on this Registration Link, and you will be provided with dial in details. To avoid delays and ensure timely connection, we encourage dialing into the conference call 15 minutes ahead of the scheduled start time.
A live webcast of the conference call will be available via the Investors section of Akebia’s website at: https://ir.akebia.com/. An online archive of the webcast can be accessed via the Investors section of Akebia’s website at http://ir.akebia.com.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. Akebia was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more information, please visit our website at www.akebia.com, which does not form a part of this release.
Akebia Therapeutics Contact
Mercedes Carrasco
mcarrasco@akebia.com
FAQ
When will Akebia (AKBA) report Q4 and full year 2025 results?
What time is the Akebia (AKBA) earnings conference call on February 26, 2026?
How can investors access Akebia (AKBA) February 26, 2026 webcast and archive?
Do I need to register to join the Akebia (AKBA) February 26, 2026 call?
What will Akebia (AKBA) discuss on the February 26, 2026 call?
